Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewStandard α2-adrenergic antagonist (Ki values are 3.5, 4.6, and 0.6 nM at cloned human α2A, α2B, and α2C-adrenoceptors respectively). Partial agonist at 5-HT1A receptors.
Available as part of the α2-Adrenoceptor Tocriset™. Diastereomer also avilable.
Rauwolscine hydrochloride is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.
M. Wt | 390.91 |
Formula | C21H26N2O3.HCl |
Storage | Store at RT |
Purity | ≥95% (HPLC) |
CAS Number | 6211-32-1 |
PubChem ID | 197067 |
InChI Key | PIPZGJSEDRMUAW-ZKKXXTDSSA-N |
Smiles | [H][C@]12C4=C(C(C=CC=C5)=C5N4)CCN1C[C@]3([H])[C@]([C@H]([C@](OC)=O)[C@@H](O)CC3)([H])C2.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility | Soluble to 5 mM in water with gentle warming and to 25 mM in DMSO with gentle warming |
References are publications that support the biological activity of the product.
Arthur et al (1993) Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Biochem.Pharmacol. 45 2337 PMID: 8517875
Hieble et al (1995) β- and γ-Adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J.Med.Chem. 38 3415 PMID: 7658428
Uhlen et al (1998) [3H]RS79948-197 binding to human, rat, guinea pig and pig α2A-, α2B-, and α2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur.J.Pharmacol. 343 93 PMID: 9551719
If you know of a relevant reference for Rauwolscine hydrochloride, please let us know.
Keywords: Rauwolscine hydrochloride, Rauwolscine hydrochloride supplier, α2-adrenoceptor, alpha2-adrenoceptor, antagonists, α2-Adrenergic, alpha2-Adrenergic, a2-adrenoceptor, a2-adrenergic, Receptors, alpha-Yohimbine, hydrochloride, a-Yohimbine, Corynanthidine, Adrenergic, Alpha-2, 0891, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Rauwolscine hydrochloride include:
Cardin and Schmidt (2004) Noradrenergic inputs mediate state dependence of auditory responses in the avian song system. J Neurosci 24 7745 PMID: 15342742
Moura et al (2006) Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br J Pharmacol 149 1049 PMID: 17075569
Do you know of a great paper that uses Rauwolscine hydrochloride from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Rauwolscine hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.